These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 17157099)

  • 21. Randomized comparison of bleeding patterns in women using a combined contraceptive vaginal ring or a low-dose combined oral contraceptive on a menstrually signaled regimen.
    Weisberg E; Merki-Feld GS; McGeechan K; Fraser IS
    Contraception; 2015 Feb; 91(2):121-6. PubMed ID: 25459098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.
    Jensen JT; Garie SG; Trummer D; Elliesen J
    Contraception; 2012 Aug; 86(2):110-8. PubMed ID: 22281416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel.
    Endrikat J; Blode H; Gerlinger C; Rosenbaum P; Kuhnz W
    Eur J Contracept Reprod Health Care; 2002 Jun; 7(2):79-90. PubMed ID: 12201326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.
    Kelly S; Davies E; Fearns S; McKinnon C; Carter R; Gerlinger C; Smithers A
    Clin Drug Investig; 2010; 30(5):325-36. PubMed ID: 20384388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combined hormonal contraception in cycles artificially extended].
    Bustillos-Alamilla E; Zepeda-Zaragoza J; Hernández-Ruiz MA; Briones-Landa CH
    Ginecol Obstet Mex; 2010 Jan; 78(1):37-45. PubMed ID: 20931801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).
    Barbosa IC; Filho CI; Faggion D; Baracat EC
    Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
    Vree ML; Schmidt J
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective follow-up of two 21/7 cycles followed by two extended regimen 84/7 cycles with contraceptive pills containing ethinyl estradiol and drospirenone.
    Seidman DS; Yeshaya A; Ber A; Amodai I; Feinstein I; Finkel I; Gordon N; Porat N; Samuel D; Shiran-Makler E; Wolman I
    Isr Med Assoc J; 2010 Jul; 12(7):400-5. PubMed ID: 20862819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Extended 30 μg Ethinyl Estradiol with Continuous Low-Dose Ethinyl Estradiol and Cyclic 20 μg Ethinyl Estradiol Oral Contraception on Adolescent Bone Density: A Randomized Trial.
    Gersten J; Hsieh J; Weiss H; Ricciotti NA
    J Pediatr Adolesc Gynecol; 2016 Dec; 29(6):635-642. PubMed ID: 27287084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison between monophasic levonorgestrel-ethinyl estradiol 150/30 and triphasic levonorgestrel-ethinyl estradiol 50-75-125/30-40-30 contraceptive pills for side effects and patient satisfaction: a study in Iran.
    Kashanian M; Shahpourian F; Zare O
    Eur J Obstet Gynecol Reprod Biol; 2010 May; 150(1):47-51. PubMed ID: 20185226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of the pharmacokinetic profile of an ascending-dose, extended-regimen combined oral contraceptive to those of other extended regimens.
    Darwish M; Bond M; Ricciotti N; Hsieh J; Fiedler-Kelly J; Grasela T
    Reprod Sci; 2014 Nov; 21(11):1401-10. PubMed ID: 24647707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel.
    Endrikat J; Cronin M; Gerlinger C; Ruebig A; Schmidt W; Düsterberg B
    Contraception; 2001 Sep; 64(3):201-7. PubMed ID: 11704101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive.
    Westhoff C; Osborne LM; Schafer JE; Morroni C
    Obstet Gynecol; 2005 Jul; 106(1):89-96. PubMed ID: 15994622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
    Poindexter AN; Burkman R; Fisher AC; LaGuardia KD
    Int J Fertil Womens Med; 2003; 48(4):163-72. PubMed ID: 13677549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended-cycle versus conventional treatment with a combined oral contraceptive containing ethinylestradiol (30 μg) and levonorgestrel (150 μg) in a randomized controlled trial.
    Hadji P; Neulen J; Schaudig K; Schwenkhagen A; Grimmbacher S; Wiegratz I
    Gynecol Endocrinol; 2020 Jun; 36(6):513-520. PubMed ID: 32064971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial.
    Oddsson K; Leifels-Fischer B; Wiel-Masson D; de Melo NR; Benedetto C; Verhoeven CH; Dieben TO
    Hum Reprod; 2005 Feb; 20(2):557-62. PubMed ID: 15539438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The contraceptive vaginal ring (NuvaRing) and hemostasis: a comparative study.
    Magnusdóttir EM; Bjarnadóttir RI; Onundarson PT; Gudmundsdóttir BR; Geirsson RT; Magnusdóttir SD; Dieben TO
    Contraception; 2004 Jun; 69(6):461-7. PubMed ID: 15157790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extended- and continuous-cycle oral contraceptives.
    Shrader SP; Dickerson LM
    Pharmacotherapy; 2008 Aug; 28(8):1033-40. PubMed ID: 18657019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative performance of a combined injectable contraceptive (50 mg norethisterone enanthate plus 5mg estradiol valerate) and a combined oral contraceptive (0.15 mg levonorgestrel plus 0.03 mg ethinyl estradiol) in adolescents.
    Molina RC; Sandoval JZ; Montero AV; Oyarzún PG; Molina TG; González EA
    J Pediatr Adolesc Gynecol; 2009 Feb; 22(1):25-31. PubMed ID: 19232299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study.
    Zahradnik HP; Hanjalic-Beck A
    Contraception; 2008 May; 77(5):337-43. PubMed ID: 18402849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.